866-997-4948(US-Canada Toll Free)

Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : Jun 2017

Category :

Pharmaceutical

No. of Pages : 146 Pages

Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2017, provides an overview of the Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline landscape.

Retinitis Pigmentosa (RP) refers to a group of diseases which cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance and x-linked inheritance.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Retinitis Pigmentosa (Retinitis) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa (Retinitis) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinitis Pigmentosa (Retinitis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 6, 2, 22 and 6 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 11 and 1 molecules, respectively.

Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Retinitis Pigmentosa (Retinitis) (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Retinitis Pigmentosa (Retinitis) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Retinitis Pigmentosa (Retinitis) (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Retinitis Pigmentosa (Retinitis) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Retinitis Pigmentosa (Retinitis) (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Retinitis Pigmentosa (Retinitis) (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Retinitis Pigmentosa (Retinitis) - Overview 7
Retinitis Pigmentosa (Retinitis) - Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 12
Products under Development by Companies 13
Products under Development by Universities/Institutes 16
Retinitis Pigmentosa (Retinitis) - Therapeutics Assessment 17
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Retinitis Pigmentosa (Retinitis) - Companies Involved in Therapeutics Development 25
Acucela Inc 25
Allergan Plc 25
Amarantus Bioscience Holdings Inc 26
Amgen Inc 26
Applied Genetic Technologies Corp 27
Asklepios BioPharmaceutical Inc 27
Astellas Pharma Inc 28
Caladrius Biosciences Inc 28
Dompe Farmaceutici SpA 29
GenSight Biologics SA 29
Grupo Ferrer Internacional SA 30
ID Pharma Co Ltd 30
InFlectis BioScience 31
Ionis Pharmaceuticals Inc 31
M's Science Corp 32
Mimetogen Pharmaceuticals Inc 32
Nanovector srl 33
Novartis AG 33
Novelion Therapeutics Inc 34
ProQR Therapeutics NV 34
ReNeuron Group Plc 35
SanBio Inc 35
Sanofi 36
Shire Plc 36
Spark Therapeutics Inc 37
Sun Pharma Advanced Research Company Ltd 38
Retinitis Pigmentosa (Retinitis) - Drug Profiles 39
A-004 - Drug Profile 39
AMRS-001 - Drug Profile 40
Antibodies to Antagonize IL-6 for Retinitis - Drug Profile 49
AP-1 - Drug Profile 50
BNP-RP - Drug Profile 51
cenegermin - Drug Profile 52
CPK-850 - Drug Profile 55
cutamesine - Drug Profile 56
FAB-111 - Drug Profile 58
Gene Therapy for Dry Macular Degeneration and Retinitis Pigmentosa - Drug Profile 59
Gene Therapy for Glaucoma and Retinitis Pigmentosa - Drug Profile 60
Gene Therapy for Ocular Diseases - Drug Profile 61
Gene Therapy for Retinitis Pigmentosa - Drug Profile 62
Gene Therapy for Retinitis Pigmentosa - Drug Profile 63
Gene Therapy to Activate Glutamate Cysteine Ligase and Glutathione Synthase for Retinitis Pigmentosa - Drug Profile 64
Gene Therapy to Activate HDAC4 for Retinitis Pigmentosa - Drug Profile 65
Gene Therapy to Activate MERTK for Retinitis Pigmentosa - Drug Profile 66
Gene Therapy to Activate mVChR1 for Retinits Pigmentosa - Drug Profile 67
Gene therapy to Activate Rhodopsin for Retinitis Pigmentosa - Drug Profile 68
Gene Therapy to Activate Rhodopsin for Retinitis Pigmentosa - Drug Profile 69
Gene Therapy to Activate RPGR for X-Linked Retinitis Pigmentosa - Drug Profile 70
GS-030 - Drug Profile 72
GT-038 - Drug Profile 75
HORAPDE-6B - Drug Profile 77
HORARLBP-1 - Drug Profile 78
IFB-088 - Drug Profile 79
IONISRHO-2.5Rx - Drug Profile 80
KIRA-6 - Drug Profile 81
KUS-187 - Drug Profile 82
LPDF-003 - Drug Profile 83
myriocin - Drug Profile 84
N-acetyl cysteine amide - Drug Profile 85
NT-501 - Drug Profile 86
OCU-100 - Drug Profile 89
QRX-411 - Drug Profile 90
ReN-003 - Drug Profile 91
RST-001 - Drug Profile 95
SAR-421869 - Drug Profile 97
SB-623 - Drug Profile 99
SHP-630 - Drug Profile 103
Small Molecule for Retinitis Pigmentosa - Drug Profile 104
Small Molecules for CNS Disorders and Ophthalmology - Drug Profile 105
Small Molecules to Block Cyclic Nucleotide Gated Channel for Retinitis Pigmentosa - Drug Profile 106
Small Molecules to Inhibit Ire1-Alpha for Retinitis Pigmentosa, Type 2 Diabetes and Amyotrophic Lateral Sclerosis - Drug Profile 107
STC-1 - Drug Profile 108
Stem Cell Therapy for AMD and Retinitis Pigmentosa - Drug Profile 109
Stem Cell Therapy for Ophthalmic Disorders - Drug Profile 110
Stem Cell Therapy for Retinitis Pigmentosa - Drug Profile 111
Stem Cell Therapy for Retinitis Pigmentosa and Age Related Macular Degeneration - Drug Profile 112
Stem Cell Therapy to Activate RPGR for Retinitis Pigmentosa - Drug Profile 114
voretigene neparvovec - Drug Profile 115
zuretinol acetate - Drug Profile 120
Retinitis Pigmentosa (Retinitis) - Dormant Projects 125
Retinitis Pigmentosa (Retinitis) - Discontinued Products 127
Retinitis Pigmentosa (Retinitis) - Product Development Milestones 128
Featured News & Press Releases 128
Appendix 141
Methodology 141
Coverage 141
Secondary Research 141
Primary Research 141
Expert Panel Validation 141
Contact Us 141
Disclaimer 142

List of Tables
Number of Products under Development for Retinitis Pigmentosa (Retinitis), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Acucela Inc, H1 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Allergan Plc, H1 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Amarantus Bioscience Holdings Inc, H1 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Amgen Inc, H1 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Applied Genetic Technologies Corp, H1 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Asklepios BioPharmaceutical Inc, H1 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Astellas Pharma Inc, H1 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Caladrius Biosciences Inc, H1 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Dompe Farmaceutici SpA, H1 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by GenSight Biologics SA, H1 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Grupo Ferrer Internacional SA, H1 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by ID Pharma Co Ltd, H1 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by InFlectis BioScience, H1 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Ionis Pharmaceuticals Inc, H1 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by M's Science Corp, H1 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Mimetogen Pharmaceuticals Inc, H1 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Nanovector srl, H1 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Novartis AG, H1 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Novelion Therapeutics Inc, H1 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by ProQR Therapeutics NV, H1 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by ReNeuron Group Plc, H1 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by SanBio Inc, H1 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Sanofi, H1 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Shire Plc, H1 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Spark Therapeutics Inc, H1 2017
Retinitis Pigmentosa (Retinitis) - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
Retinitis Pigmentosa (Retinitis) - Dormant Projects, H1 2017
Retinitis Pigmentosa (Retinitis) - Dormant Projects, H1 2017 (Contd..1), H1 2017
Retinitis Pigmentosa (Retinitis) - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Retinitis Pigmentosa (Retinitis), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *